REFERENCES
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Alimta, 2009. http://www. accessdata. fda.gov/drugsatfda_docs/Label/2009/021462s021lbl.pdf [accessed October 17, 2009].
- Michels J, Spano JP, Brocheriou I, Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;2:53–56.
- Castro M. Thymidine rescue: An antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol. 2003;21:4066–4069.
- Takimoto CH, Hammond-Thelin LA, Latz JE, Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res. 2007;13:2675–2683.
- van den Bogaert DP, Pouw EM, van Wijhe G, Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2006;1:25–30.
- Llombart-Cussac A, Martin M, Harbeck N, A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res. 2007;13:3652–3659.
- Jassem J, Ramlau R, Santoro A, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–1704.
- Vootukuru V, Liew YP, Nally JV. Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol. 2006; 23:419–422.
- Moses AM, Scheinman SJ, Oppenheim A. Marked hypotonic polyuria resulting from nephrogenic diabetes insipidus with partial sensitivity to vasopressin. J Clin Endocrinol Metab. 1984;59:1044–1049.
- Garofeanu CG, Weir M, Rosas-Arellano MP, Causes of reversible nephrogenic diabetes insipidus: A systematic review. Am J Kidney Dis. 2005;45:626–637.
- Fernández-Espartero MC, Rodríguez M, de la Mata J. Methotrexate-induced nephrogenic diabetes insipidus: First case report. Rheumatology (Oxford). 2002;41:233–234.
- Mita AC, Sweeney CJ, Baker SD, Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24:552–562.
- Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007;6:404–417.
- Collins JF. Novel insights into intestinal and renal folate transport. Focus on ‘Apical membrane targeting and trafficking of the human proton-coupled folate transporter in polarized epithelia.' Am J Physiol Cell Physiol. 2008;294: C381–C382.
- Damaraju VL, Hamilton KF, Seth-Smith ML, Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney. Mol Pharmacol. 2005;67:453–459.